AR and Familial prostate cancer: In prostate cancer, BET protein inhibitors modulate AR signaling and enhance the anti-androgenic effect of AR-targeted therapies in AR positive prostate cancer cells such as VCaP and LNCaP cells, making them suitable drugs for treatment of mCRPCs (113–116).